Industry
Industry — Understand the Playing Field
Molina Healthcare is a pure-play government managed care organization: it collects a fixed monthly fee from a state Medicaid agency or from federal Medicare/Marketplace programs for every covered life, and takes the risk of paying those members' medical bills. The economics are a regulated spread — premium in, medical cost out, a thin slice in between.
In FY2025 MOH took in $43.1B of premium revenue and paid out $39.5B in medical costs — a Medical Care Ratio (MCR) of 91.7%. The remaining 8.3% had to cover administration, taxes, interest, and shareholder return. A 100 bp move in MCR can swing a year of earnings by more than half — which is why how rates are set and how costs trend is the framing for everything else in this report.
US Medicaid spending (FY24, $B)
MOH premium revenue ($B)
MOH FY25 MCR
MOH FY25 pre-tax margin
The one number to remember: MCR (Medical Care Ratio). It is medical costs divided by premium revenue. In a year where MCR is 89% the business earns acceptable margins. In a year where MCR is 92% — like 2025 — pre-tax margin collapses from ~4% to ~1%. The industry is now in such a year and every conversation about MOH's investment case is, downstream, a conversation about whether 2026 is the trough.
1. What is "managed care" actually selling?
A state Medicaid agency or CMS (Centers for Medicare & Medicaid Services) writes a recurring per-member-per-month (PMPM) check to the health plan. In return, the plan enrolls a defined population, builds a provider network, pays medical claims, manages utilization, and stays within a regulator-set minimum medical-loss ratio (the floor below which margins are clawed back).
The plan keeps three risks:
What the plan does not take is the financing risk: state and federal taxpayers fund the premium pool. Managed care is therefore a regulated profit-pool — closer to a defense contractor with a clinical mission than to a commercial P&C insurer.
2. The value chain — where the dollars actually go
Out of every premium dollar an MCO collects, roughly 88-92 cents pays providers (hospitals, physicians, pharmacies, behavioral health, long-term services), 6-7 cents pays administration, and the remaining 1-5 cents is operating income that then has to cover interest, tax, and shareholder return.
The retained sliver shrank from 4.4 cents to 1.8 cents in a single year. Almost all of the difference went to providers — utilization (more office visits, more specialty drugs, more behavioral health) ran ahead of the rates states had set. No SG&A explosion, no acquisition write-down, no failed product. The compression is mechanical to the spread model.
Two facts jump out. The profit pool is enormous in absolute dollars — UnitedHealth alone earned almost $19B of operating income on roughly $448B of revenue. And 2025 was a uniformly tough year: Centene printed a $7.6B operating loss after a Marketplace risk-adjustment miss; UNH's operating income fell ~40%; Humana's halved from its 2022-23 peak. The cost shock is industry-wide, not idiosyncratic to MOH.
3. The three business lines — different rates, different rules
MOH reports under one industry banner but runs three economically distinct products with different counterparties, pricing cycles, and political risk.
Every segment got worse. Marketplace deteriorated 1,520 bps in a single year — the dictionary definition of a mis-priced book — and explains the FY2026 Marketplace exit. Medicaid, which dominates the mix, moved 150 bps to 91.8% — uncomfortable but inside the historical band. Medicare moved 330 bps and pushed the company to exit the MAPD product line entirely.
4. The peer arena — who actually plays in this market
The US public health-plan market is dominated by six listed players with radically different DNA:
Three observations:
Scale matters but is not destiny. UNH is roughly 10x MOH's revenue and earns ~25x the operating income, but scale did not insulate it — UNH's FY2025 operating income still fell 40%.
The market values diversification heavily. UNH trades at 0.90x EV/Revenue; MOH and Centene at 0.11-0.13x — a 7-8x discount. Part of that is justified (MOH's revenue dollar lacks Optum's services and PBM economics); the rest is what bulls underwrite closing as MCR normalises.
Centene is MOH's mirror. CNC's 2025 wipeout — a $7.6B operating loss from a Marketplace risk-adjustment miss — is the failure mode MOH narrowly avoided. The bear case is "this could be you next quarter"; the bull case is "MOH's Medicaid book is cleaner and the trough is shorter."
The bottom-left quadrant — low multiple, low/negative profit — is where the two pure-play government insurers live. UnitedHealth sits top-right; diversified payors (CVS, ELV, HUM) in the middle. The question for the rest of the report is whether MOH is mispriced (trough earnings + cycle recovery) or correctly priced (structurally lower-margin than its peers).
5. The MCR cycle — why this is a cyclical business, not a mature one
Medicaid managed care is a regulated cycle, not a steady-state utility. The cycle has four stages and roughly a 3-5 year period:
MOH's own twenty-year history shows this cycle clearly. The chart below traces the company-wide MCR proxy (medical cost ÷ total revenue) and operating margin over two decades. Three full cycles are visible:
MCR moves first, margin follows inversely. The 2017 spike (a $555M operating loss) was a Marketplace re-pricing shock; the 2018-2020 trough was the corresponding margin recovery. The 2009-2012 saucer was a slower Medicaid rate-lag cycle. The 2025 spike — back above 86% — is the latest occurrence of the same pattern.
Note on the MCR proxy. MOH's reported "MCR" uses premium revenue as the denominator (91.7% in FY2025). The chart above uses total revenue (which adds investment income and premium-tax revenue), giving a lower number around 87%. The shape and direction of the curve are identical; only the absolute level differs. Use the lower number for cross-year comparison, the 91.7% for current-year context.
6. The 2025-2026 regulatory shock — three policy changes investors must understand
What makes the current cycle different from prior cycles is that three regulatory changes are landing simultaneously, each of which alone would be significant:
The "acuity shift" mechanic is subtle and important. When healthy people drop off Medicaid (redetermination), the remaining book is sicker. Per-member cost rises automatically — even if no individual member's medical use changed. State rate-setting processes typically take 12-18 months to recognise the new mix, so MCR runs hot in the interim. This is exactly what MOH says is happening now: "rate changes typically lag changes in cost trends."
7. Demand drivers — why the industry will be larger five years from now
Despite the near-term shocks, the structural demand picture for government-sponsored managed care remains favourable. Three secular drivers are independent of the current MCR cycle:
MOH's own framing is consistent with these drivers: management has set a long-term premium-revenue growth target of 11-13% and reiterated a $50B premium revenue target for 2027. Whether the cycle co-operates is what determines whether earnings growth keeps pace with revenue growth.
8. The investor scoreboard — KPIs to watch
Read the rest of this report through this lens. These eight metrics are how every analyst, every CFO, and every state regulator tracks the industry:
9. Industry attractiveness — a beginner's verdict
Putting the pieces together, here is how this industry stacks up:
The industry verdict. Government managed care is a large, low-margin, regulatory-cyclical business with high recurrence but real cycle risk. Investors should not expect smooth compounding here — they should expect 3-5 year MCR cycles, periodic political shocks, and a few years out of every five where the multiple compresses sharply. The historical record (post-2012, post-2017) shows that the same forces that compress margins eventually restore them, but the timing is set by 50 state legislatures, CMS, and Congress — not by the management teams of the listed payors.
10. What to carry into the rest of this report
- MOH is a pure-play government MCO. 75% Medicaid, 14% Medicare, 10% Marketplace. Closest comp is Centene; closest contrast is UnitedHealth.
- MCR is the master variable. 91.7% in FY25 vs. 88-90% target. ~$430M of pre-tax income per 100 bps.
- 2025-2026 is a regulatory-shock year. OBBBA passed, ACA enhanced subsidies expired, redeterminations continue — together they frame the 50%+ stock drawdown from late 2024.
- The cycle has historical precedent. 2009-12, 2017, and 2024-26 all show the same MCR overshoot → margin compression → rate catch-up pattern. The 2017 recovery took ~18 months and ended in a 6% operating margin print.
- MOH's seat at the table. Not a Star Ratings story (HUM), not a vertical-integration story (UNH/Optum), not a diversified-payor story (ELV/CVS). The investment case is fundamentally a Medicaid rate-cycle and RFP-execution story.